| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
Review |
1 Cattedra di Endocrinologia, Istituto di Medicina Interna, Malattie Endocrine e del Metabolismo, University of Catania, Ospedale Garibaldi, Catania, Italy
2 IMO, Istituto Mediterraneo di Oncologia, Catania, Italy
3 Cattedra di Endocrinologia e Malattie del Metabolismo, Dipartimento di Medicina Sperimentale eClinica, University of Catanzaro "Magna Graecia", Policlinico Mater Domini,Catanzaro, Italy
Correspondence: Dr Belfiore belfiore{at}unicz.it
In recent years, the activation of the insulin-like growth factor (IGF) system in cancer has emerged as a key factor for tumour progression and resistance to apoptosis. Therefore, a variety of strategies have been developed to block the type I IGF receptor (IGF-I-R), which is thought to mediate the biological effects of both IGF-I and IGF-II. However, recent data suggest that the IGF signalling system is complex and that other receptors are involved. To unravel the complexity of the IGF system in thyroid cancer, IGF-I and IGF-II production, and the expression and function of their cognate receptors were studied. Both IGFs were found to be locally produced in thyroid cancer: IGF-I by stromal cells and IGF-II by malignant thyrocytes. Values were significantly higher in malignant tissue than in normal tissue. IGF-I-Rs were overexpressed in differentiated papillary carcinomas but not in poorly differentiated or undifferentiated tumours, whereas insulin receptors (IRs) were greatly overexpressed in all tumour hystotypes, with a trend for higher values in dedifferentiated tumours. As a consequence of IR overexpression, high amounts of IR/IGF-I-R hybrids (which bind IGF-I with high affinity) were present in all thyroid cancer histotypes. Because of recent evidence that isoform A of IR (IR-A) is a physiological receptor for IGF-II in fetal life, the relative abundance of IR-A in thyroid cancer was measured. Preliminary data indicate that overexpressed IRs mainly occur as IR-A in thyroid cancer. These data indicate that both IR/IGF-I-R hybrids and IR-A play an important role in the overactivation of the IGF system in thyroid cancer and in IGF-I mitogenic signalling in these tumours. J Clin Pathol: Mol Pathol
Key Words: insulin-like growth factor system • insulin receptor • insulin-like growth factor I receptor
This article has been cited by other articles:
|
|
 |
|
  A. Navarrete Santos, N. Ramin, S. Tonack, and B. Fischer Cell Lineage-Specific Signaling of Insulin and Insulin-Like Growth Factor I in Rabbit Blastocysts Endocrinology, February 1, 2008; 149(2): 515 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Ren, Q. Guan, X. Zhong, B. Gong, Y. Sun, W. Xin, J. Guo, H. Wang, L. Gao, and J. Zhao Phosphatidylinositol 3-kinase/nuclear factor-{kappa}B signaling pathway is involved in the regulation of IGF-I on Fas-associated death domain-like interleukin-1-converting enzyme-inhibitory protein expression in cultured FRTL thyroid cells J. Mol. Endocrinol., June 1, 2007; 38(6): 619 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Wiseman, H. Masoudi, P. Niblock, D. Turbin, A. Rajput, J. Hay, S. Bugis, D. Filipenko, D. Huntsman, and B. Gilks Anaplastic Thyroid Carcinoma: Expression Profile of Targets for Therapy Offers New Insights for Disease Treatment Ann. Surg. Oncol., February 1, 2007; 14(2): 719 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Blanquart, C. Gonzalez-Yanes, and T. Issad Monitoring the Activation State of Insulin/Insulin-Like Growth Factor-1 Hybrid Receptors Using Bioluminescence Resonance Energy Transfer Mol. Pharmacol., November 1, 2006; 70(5): 1802 - 1811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aiello, G. Pandini, F. Frasca, E. Conte, A. Murabito, A. Sacco, M. Genua, R. Vigneri, and A. Belfiore Peroxisomal Proliferator-Activated Receptor-{gamma} Agonists Induce Partial Reversion of Epithelial-Mesenchymal Transition in Anaplastic Thyroid Cancer Cells Endocrinology, September 1, 2006; 147(9): 4463 - 4475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Wang, G. Chakravarty, S. Kim, Y. D. Yazici, M. N. Younes, S. A. Jasser, A. A. Santillan, C. D. Bucana, A. K. El-Naggar, and J. N. Myers Growth-Inhibitory Effects of Human Anti-Insulin-Like Growth Factor-I Receptor Antibody (A12) in an Orthotopic Nude Mouse Model of Anaplastic Thyroid Carcinoma Clin. Cancer Res., August 1, 2006; 12(15): 4755 - 4765. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Cabanas, T Garcia-Caballero, J Barreiro, L Castro-Feijoo, R Gallego, T Arevalo, R Canete, and M Pombo Papillary thyroid carcinoma after recombinant GH therapy for Turner syndrome Eur. J. Endocrinol., October 1, 2005; 153(4): 499 - 502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Blanquart, N. Boute, D. Lacasa, and T. Issad Monitoring the Activation State of the Insulin-Like Growth Factor-1 Receptor and Its Interaction with Protein Tyrosine Phosphatase 1B Using Bioluminescence Resonance Energy Transfer Mol. Pharmacol., September 1, 2005; 68(3): 885 - 894. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. N. Younes, O. G. Yigitbasi, Y. W. Park, S.-J. Kim, S. A. Jasser, V. S. Hawthorne, Y. D. Yazici, M. Mandal, B. N. Bekele, C. D. Bucana, et al. Antivascular Therapy of Human Follicular Thyroid Cancer Experimental Bone Metastasis by Blockade of Epidermal Growth Factor Receptor and Vascular Growth Factor Receptor Phosphorylation Cancer Res., June 1, 2005; 65(11): 4716 - 4727. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Nagle, Z. Ma, M. A. Byrne, M. F. White, and L. M. Shaw Involvement of Insulin Receptor Substrate 2 in Mammary Tumor Metastasis Mol. Cell. Biol., November 15, 2004; 24(22): 9726 - 9735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Vella, R. Mineo, F. Frasca, E. Mazzon, G. Pandini, R. Vigneri, and A. Belfiore Interleukin-4 Stimulates Papillary Thyroid Cancer Cell Survival: Implications in Patients with Thyroid Cancer and Concomitant Graves' Disease J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2880 - 2889. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Poulaki, C. S. Mitsiades, C. McMullan, D. Sykoutri, G. Fanourakis, V. Kotoula, S. Tseleni-Balafouta, D. A. Koutras, and N. Mitsiades Regulation of Vascular Endothelial Growth Factor Expression by Insulin-Like Growth Factor I in Thyroid Carcinomas J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5392 - 5398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Pandini, E. Medico, E. Conte, L. Sciacca, R. Vigneri, and A. Belfiore Differential Gene Expression Induced by Insulin and Insulin-like Growth Factor-II through the Insulin Receptor Isoform A J. Biol. Chem., October 24, 2003; 278(43): 42178 - 42189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pandini, F. Frasca, R. Mineo, L. Sciacca, R. Vigneri, and A. Belfiore Insulin/Insulin-like Growth Factor I Hybrid Receptors Have Different Biological Characteristics Depending on the Insulin Receptor Isoform Involved J. Biol. Chem., October 11, 2002; 277(42): 39684 - 39695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Poulaki, C. S. Mitsiades, V. Kotoula, S. Tseleni-Balafouta, A. Ashkenazi, D. A. Koutras, and N. Mitsiades Regulation of Apo2L/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Thyroid Carcinoma Cells Am. J. Pathol., August 1, 2002; 161(2): 643 - 654. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Molecular Pathology | Journal of Clinical Pathology |
